Albuquerque Neuroscience Inc., which researches central nervous system diseases in humans, has been acquired by The IMA Group, a New York-based provider of medical and psychological screening services.
The deal was announced on Sept. 9. The terms of the deal were not disclosed.
Under the transaction, Albuquerque Neuroscience will join IMA's clinical research division, which specializes in clinical trials for a variety of therapeutic areas. The Albuquerque company offers "deep therapeutic experience" in Alzheimer’s Disease, vascular dementia, insomnia, pain management, fibromyalgia, constipation and sexual dysfunction, according to a release from the IMA Group.
In addition, the deal "broadens IMA’s access to diverse patient populations," the release says.
“We are pleased to be joining the IMA clinical research trial network. Our long-standing expertise in [central nervous system] disorders complements the existing capabilities of IMA Clinical Research and will further accelerate our growth trajectory,” Albuquerque Neuroscience cofounder Geraldine Dempsey said in a prepared statement.
Albuquerque Neuroscience, which was incorporated in 1997 and located at 101 Hospital Loop NE, will continue to operate under its current name and "key leadership and staff" will remain in place, according to IMA's news release.
Albuquerque Neuroscience is at least the second recent health care company acquisition in New Mexico. Two months ago, in July, Texas-based Addus HomeCare Corp., which provides at-home health care unveiled plans to purchase Albuquerque health company Armada Skilled Homecare Services, Business First reported.
